For instance, exogenous miR148a could be administered to boost its levels and effect on CYP3A4 and CYP2C19 in GI tumors, head & neck cancers, breast cancer, lung cancer and melanoma [80]. This evidence concerns the gene CYP2C19 and head and neck cancer.